Filing Analysis
Zeo ScientifiX, Inc. amended the Certificate of Designation for its Series C Non-Convertible Preferred Stock. The amendment modifies redemption provisions and assignment rights for holders Skycrest Holdings, Inc. and Greyt Ventures LLC, who control 25.5% of total voting power.
🚩 Red Flags
- Concentrated voting power: Two entities (Skycrest and Greyt) control 25.5% of total voting power, which is significant for a micro-cap.
- Modification of redemption rights: Changing the terms under which preferred shares can be redeemed or assigned often signals negotiations to facilitate liquidity or restructuring for major stakeholders.
📋 Key Facts
- Amendment filed on December 17, 2024, with the Secretary of State of Nevada.
- Affects Series C Non-Convertible Preferred Stock held by Skycrest Holdings, Inc. and Greyt Ventures LLC.
- Skycrest and Greyt collectively exercise 25.5% of total voting power via a change in control transaction from August 2022.
- Amendment allows assignment of Series C shares without triggering redemption provisions, subject to Board consent.
- Amendment lowers the threshold of common stock ownership that triggers redemption provisions for Skycrest or Greyt.
Zeo ScientifiX, Inc. is filing an amendment to its previous 8-K to correct graphical errors in a PowerPoint presentation used during a medical meeting. The presentation featured the company's new product, ZEO HAIR GROW™, developed in collaboration with Exotropin, LLC.
🚩 Red Flags
- Correction of 'graphical errors' in marketing/product presentation materials can sometimes mask data inaccuracies, though here it is specifically noted as graphical.
📋 Key Facts
- The filing is an Amendment (8-K/A) to a report filed on November 15, 2024.
- The purpose of the amendment is to furnish a corrected version of a PowerPoint presentation due to 'graphical errors' in the original slides.
- The presentation was delivered by Dr. Robin L. Smith at the Medical Aesthetics Professionals (MAP) meeting in Scottsdale, Arizona.
- ZEO holds a minority equity interest in Exotropin, LLC, its collaborator on product development.
Zeo ScientifiX, Inc. is disclosing a presentation to be given by Dr. Robin L. Smith at the Medical Aesthetics Professionals meeting regarding exosomes and their product 'ZEO HAIR GROW™ Powered By Exotropin™'. The filing is made under Regulation FD to ensure fair disclosure of non-public information via a PowerPoint presentation.
🚩 Red Flags
- Potential related-party connection: ZEO holds an equity interest in the collaborator/partner company (Exotropin, LLC).
📋 Key Facts
- Dr. Robin L. Smith (co-founder of Exotropin, LLC) will present at the Medical Aesthetics Professionals meeting in Scottsdale, AZ on November 15, 2024.
- The presentation topic is 'Exosomes are the new Frontier in Aesthetics: Not All Exosomes are Alike'.
- ZEO holds a minority equity interest in Exotropin, LLC.
- ZEO is collaborating with Exotropin on product development, specifically mentioning 'ZEO HAIR GROW™ Powered By Exotropin™'.
Zeo ScientifiX, Inc. announced the upcoming introduction of its first collaborative product, ZEO HAIR GROW™ Powered By Exotropin™, at a medical aesthetics meeting in Scottsdale, Arizona.
🚩 Red Flags
- Related-party transaction potential: ZEO holds a minority equity interest in the partner company (Exotropin, LLC), which could lead to conflicts of interest regarding product terms and valuations.
📋 Key Facts
- Product name: ZEO HAIR GROW™ Powered By Exotropin™
- Collaboration partner: Exotropin, LLC (privately-held developer of cosmeceuticals)
- ZEO holds a minority equity interest in Exotropin, LLC
- Product launch/introduction event: Medical Aesthetics Professionals meeting, Scottsdale, AZ (Nov 14-16, 2024)
Zeo ScientifiX, Inc. issued an 8-K to announce the launch of a new monthly regenerative medicine educational event series aimed at healthcare providers and staff.
📋 Key Facts
- The company launched a monthly regenerative medicine educational event on October 15, 2024.
- Target audience for the events includes healthcare providers and their medical staff.
- The announcement was made via a press release included as Exhibit 99.1.
Zeo ScientifiX, Inc. (ZEOX) announced a strategic partnership with Physicians Group, LLC to collaborate on future clinical trials for the company's biologic therapies. The collaboration aims to leverage Physicians Group's network of 75 clinics and 750+ personnel to accelerate research objectives and patient enrollment.
🚩 Red Flags
- Interim CEO/CFO: Ian Bothwell currently holds both the Interim CEO and CFO positions, which can indicate management instability or transition periods common in micro-cap companies.
📋 Key Facts
- Partnered with Physicians Group, LLC, a multi-state provider organization operating 75 clinics.
- Physicians Group employs over 750 clinical personnel and treats 1,500–2,000 patients per month.
- Collaboration focus: Clinical trials for ZEO's products, specifically targeting musculoskeletal conditions.
- ZEO has completed Phase 1 trials for its flagship product, Zofin™, and is seeking to launch Phase 2 trials.
- The partnership aims to provide access to experienced clinicians and qualified subjects for clinical enrollment.
Zeo ScientifiX, Inc. provided a business strategy update highlighting the successful completion of Phase 1 clinical trials for its flagship product, Zofin™, and plans to initiate Phase 2 trials. The company is also expanding into aesthetic/anti-aging applications through a partnership with Exotropin, LLC.
🚩 Red Flags
- Interim CEO is also serving as the CFO (Ian Bothwell), indicating potential management instability or resource constraints common in micro-caps.
- Heavy reliance on forward-looking statements regarding clinical trial success and market growth.
📋 Key Facts
- Completed Phase 1 clinical trials for proprietary product Zofin™.
- Actively seeking to launch Phase 2 clinical trials for Zofin™ across several indications.
- Partnered with Exotropin, LLC to develop topical aesthetic and anti-aging products.
- ZEO holds a minority interest in Exotropin, LLC.
- The company operates a cGMP compliant laboratory at Nova Southeastern University.
- Company name was changed from Organicell Regenerative Medicine to ZEO ScientifiX in February 2024.
Zeo ScientifiX, Inc. granted warrants to two consultants who are also the company's controlling stockholders. Additionally, the company issued significant stock options to various directors and executive officers.
🚩 Red Flags
- Related-party transaction: Warrants granted to controlling stockholders (Skycrest Holdings, LLC and Greyt Ventures LLC).
- Potential dilution: Issuance of 700,000 warrants plus 475,000 options represents significant potential dilution for existing shareholders.
- Piggy-back registration rights granted to controlling stockholders can lead to future large-scale selling pressure.
📋 Key Facts
- Granted 350,000 warrants each (700,000 total) to Skycrest Holdings, LLC and Greyt Ventures LLC.
- Skycrest Holdings, LLC and Greyt Ventures LLC are identified as the controlling stockholders of the Company.
- Warrants vest in equal monthly installments over 18 months; exercisable for 10 years at $2.35 per share.
- Consultants were granted piggy-back registration rights for shares issuable upon exercise.
- Granted stock options to five individuals (including Interim CEO/CFO Ian T. Bothwell) totaling 475,000 shares under the 2021 Incentive Stock Plan.
- All options and warrants have an exercise price of $2.35 per share.
Zeo ScientifiX, Inc. completed a $500,000 private financing on July 8, 2024, involving the issuance of common stock and warrants to a single accredited investor. The deal includes piggy-back registration rights and related-party supply/investment agreements with affiliates of the investor.
🚩 Red Flags
- Concentration risk: Financing provided by a single accredited investor.
- Potential dilution: Issuance of 250,000 shares plus 83,333 warrant shares.
- Related-party transactions: Supply agreement and potential investment terms involve affiliates of the primary financier.
📋 Key Facts
- Completed $500,000 private financing on July 8, 2024.
- Issued 250,000 shares of common stock to a single accredited investor.
- Issued warrants for 83,333 additional shares at an exercise price of $2.00 per share.
- Warrants are exercisable on a 'cashless' basis and have a ten-year term.
- Investor granted piggy-back registration rights under the Securities Act.
- Entered into a supply agreement with an affiliate of the Investor.
- Signed a non-binding term sheet for an affiliate to potentially invest in a new clinical trial subsidiary.
Zeo ScientifiX, Inc. announced the non-renewal of employment agreements for its CEO (Dr. Harry Leider) and CSO (Dr. Howard Golub), effective May 31, 2024. The CFO, Ian T. Bothwell, has been appointed as Interim CEO while the board searches for permanent replacements.
🚩 Red Flags
- Simultaneous departure of both Chief Executive Officer (CEO) and Chief Science Officer (CSO).
- Leadership vacuum in critical scientific and executive roles.
- Potential for legal/financial dispute regarding severance claims from the former CEO.
📋 Key Facts
- CEO Dr. Harry Leider's employment agreement was not renewed; he also ceased serving as a director on May 31, 2024.
- CSO Dr. Howard Golub's employment agreement was not renewed, effective May 31, 2024.
- CFO Ian T. Bothwell appointed as Interim CEO effective June 1, 2024.
- The company is currently searching for permanent CEO and CSO candidates.
- Dr. Leider may seek severance, though the company believes he is not entitled to any under his contract.
Zeo ScientifiX, Inc. announced several compensation-related actions on April 1, 2024, including stock grants to board members and a salary increase for the CFO.
🚩 Red Flags
- Immediate vesting of large stock grants (187,500 total shares) to board members can be seen as aggressive compensation timing.
- Retroactive salary increase for the CFO.
📋 Key Facts
- Awarded 125,000 shares of common stock to director Jerry Glauser (vested immediately).
- Awarded 62,500 shares of common stock to director Leathem Stearn (vested immediately).
- Granted stock options for 5,000 shares each to independent directors Chuck Bretz, Jerry Glauser, Leathem Stearn, and Gurvinder Pal Singh.
- Options have an exercise price of $2.00 per share and vest in two tranches (half immediately, half on September 23, 2024).
- Increased CFO Ian T. Bothwell's base salary to $250,000, retroactive to January 1, 2024.
Zeo ScientifiX, Inc. (formerly Organicell Regenerative Medicine, Inc.) announced the completion of FINRA's review regarding its corporate name change and ticker symbol update from 'OCEL' to 'ZEOX'. The new symbol is scheduled to take effect on March 5, 2024.
📋 Key Facts
- Corporate name changed from Organicell Regenerative Medicine, Inc. to Zeo ScientifiX, Inc., effective February 20, 2024.
- Trading symbol changing from 'OCEL' to 'ZEOX'.
- The change is effective with the opening of trading on March 5, 2024.
- FINRA has completed the review and processing of the Issuer Company-Related Action Notification Form.
Zeo ScientifiX, Inc. (formerly Organicell Regenerative Medicine, Inc.) has filed an amendment to its Articles of Incorporation to officially change its corporate name. This change is part of a broader rebranding effort and includes a pending request for a new trading symbol with FINRA.
📋 Key Facts
- Effective date of name change: February 20, 2024.
- Former name: Organicell Regenerative Medicine, Inc.
- New name: Zeo ScientifiX, Inc.
- The company has submitted an Issuer Company-Related Action Notification Form to FINRA regarding the name and symbol change.
- A new trading symbol is pending FINRA review.